PARP1 and medulloblastoma: Despite promising data from PARP inhibitors like niraparib and olaparib (Murai et al., 2012), given that veliparib is the most clinically tested PARP inhibitor for children with brain cancer, we investigated a potential role for veliparib in medulloblastoma to ensure rapid clinical translatability.